Warm autoimmune hemolytic anemia (AIHA) is the most prevalent type of AIHA and is characterized by the destruction of red blood cells by warm autoantibodies optimally reactive at 37°C1. Current therapeutic interventions for warm AIHA include corticosteroids,
rituximab, and surgical splenectomy. Many patients, however, cannot be treated with these therapies and may experience severe side effects2. In order to provide effective and definitive therapy for patients with primary warm AIHA, close collaboration between clinicians and laboratories may be needed3. Here, we describe how appropriate and timely laboratory practices led to proper therapeutic management, particularly when combined with the prompt recognition of the patient as a regular repeat blood donor.



Chuan-Shi Liu - Medical Laboratory Division, Taichung Veterans General Hospital, Chiayi City, Taiwan

Jun Yu Woon - Department of Microbiology, Immunology and Biopharmaceuticals, National Chiayi University, Chiayi City, Taiwan

Yu-Ting Chiu - Department of Laboratory Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan

Shih-Chien Lu - Department of Medical Laboratory Science and Biotechnology, Chung Hwa University of Medical Technology, Tainan, Taiwan; Tainan Blood Center, Taiwan Blood Services Foundation, Tainan, Taiwan

Li-Te Chin - Tainan Blood Center, Taiwan Blood Services Foundation, Tainan, Taiwan; Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei City, Taiwan

  • Abstract viewed - 393 times
  • pdf downloaded - 141 times